Ionis Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $2,990.1 Mil.
During the past 12 months, Ionis Pharmaceuticals's average Total Assets Growth Rate was 20.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 9.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -0.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 19.00% per year.
During the past 13 years, Ionis Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 162.30%. The lowest was -21.60%. And the median was 9.80%.
Total Assets is connected with ROA %. Ionis Pharmaceuticals's annualizedROA % for the quarter that ended in Dec. 2023 was -1.25%. Total Assets is also linked to Revenue through Asset Turnover. Ionis Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.
Ionis Pharmaceuticals Total Assets Historical Data
The historical data trend for Ionis Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Ionis Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
3,233.11
2,389.76
2,611.69
2,533.88
2,990.07
Ionis Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
2,533.88
2,885.22
2,971.13
2,933.97
2,990.07
Ionis Pharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Ionis Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (NAS:IONS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Ionis Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Ionis Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 